Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

WHO pandemic agreement.

Norton A. et al, (2025), BMJ, 390

Ciprofloxacin versus Aminoglycoside-Ciprofloxacin for Bubonic Plague.

Randremanana RV. et al, (2025), N Engl J Med, 393, 544 - 555

Vaccine effects on in-hospital COVID-19 outcomes.

Gonçalves BP. et al, (2025), Epidemiology

Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)

Horby PW. et al, (2025), Lancet Infectious Diseases

Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2025), Lancet Infect Dis

Observational study on the clinical epidemiology of infectious acute encephalitis syndrome including Nipah virus disease, Bangladesh: BASE cohort study protocol

Hassan MZ. et al, (2025)

Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo.

PALM007 Writing Group None. et al, (2025), N Engl J Med, 392, 1484 - 1496

Detection of mpox and other orthopoxviruses using a lateral flow device as a point-of-care diagnostic.

Laidlaw SM. et al, (2025), Microbiol Spectr, 13

Europe needs a sustainably funded influenza research and response network.

Krammer F. et al, (2025), Lancet Infect Dis, 25, 369 - 372

Ebola disease: bridging scientific discoveries and clinical application.

Rojek A. et al, (2025), Lancet Infect Dis, 25, e165 - e176

Embedding treatment in stronger care systems.

Rojek A. et al, (2025), Lancet Infect Dis, 25, e177 - e188

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2025), EClinicalMedicine, 81

Multi-antigen serology and a diagnostic algorithm for the detection of arbovirus infections as novel tools for arbovirus preparedness in southeast Europe (MERMAIDS-ARBO): a prospective observational study.

Kasbergen LMR. et al, (2025), Lancet Infect Dis

Prevalence, clinical management, and outcomes of adults hospitalised with endemic arbovirus illness in southeast Europe (MERMAIDS-ARBO): a prospective observational study.

Sigfrid L. et al, (2025), Lancet Infect Dis

Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics.

Bourner J. et al, (2025), Emerg Infect Dis, 31, 9 - 16

Improving clinical care of patients in Nipah outbreaks: moving beyond 'compassionate use'.

Hassan MZ. et al, (2025), Lancet Reg Health Southeast Asia, 33

Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)

Horby PW. et al, (2025)

Clinical characterisation and outcomes of human clade IIb mpox virus disease - a European multicentre observational cohort study (MOSAIC).

Pesonel E. et al, (2025), Clin Infect Dis

'Involve those who are managing these outbreaks': stakeholders' perspectives on the barriers and facilitators to the implementation of clinical management guidelines for high-consequence infectious diseases in Uganda-a thematic network analysis.

Kabajaasi O. et al, (2025), BMJ Public Health, 3

The Modern Landscape of Ebola Disease 1 Ebola disease: bridging scientific discoveries and clinical application

Rojek A. et al, (2025), LANCET INFECTIOUS DISEASES, 25, e165 - e176

Load More

1
2
3
4
5

Include forthcoming?